Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Psilocybin and SIRT on Gut-Brain Axis Biomarkers and Depression in Trauma-Related MDD
NCT07703722Phase 3Recruiting
- Sponsor
- Khyber Medical University
- Start
- Apr 2026
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Phase 3, randomised trial of psilocybin in major depressive disorder (MDD) (4 arms), sponsored by Khyber Medical University. Primary endpoints: Depression Severity at Week 12, Trauma-Related Symptoms at Week 12 and 2 more. Started Apr 2026; status: recruiting.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07703722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07703722.